Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Fengqie Pingchuan Plaster is a traditional Chinese medicine (TCM) rubber plaster developed and manufactured by Anhui Anke Yuliangqing Pharmaceutical. It is primarily indicated for the relief of asthma and chronic bronchitis symptoms. The formulation's key active ingredient is *Datura metel* (Fengqie), which contains tropane alkaloids such as hyoscyamine, scopolamine, and atropine. These compounds function as muscarinic acetylcholine receptor antagonists, providing bronchodilation and reducing airway secretions. The drug is applied topically as a plaster, often to specific acupuncture points, allowing for the transdermal absorption of active components to provide localized and systemic relief of wheezing and coughing. It is an approved pharmaceutical product in China.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Fengqie Pingchuan Plaster.